NHSE

Creating headroom: can cutting spend on low-value prescriptions fund new drugs?

August 11, 2017

Can reducing NHS spending on ‘low-value’ prescriptions help fund new drugs?

Creating headroom: can cutting spend on low-value prescriptions fund new drugs?

https://pharmaphorum.com/views-and-analysis/creating-headroom-prescriptions-new-drugs/

Budget impact and cost effectiveness: alternatives to NICE and NHSE proposals

January 17, 2017

A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.

Budget impact and cost effectiveness: alternatives to NICE and NHSE proposals

https://pharmaphorum.com/views-and-analysis/budget-impact-cost-effectiveness-alternatives-nice-nhse-proposals/

Budget impact and cost effectiveness: Can the UK learn from ICER in the US?

January 12, 2017

Leela Barham examines the approach of the Institute for Clinical and Economic Review.

Budget impact and cost effectiveness: Can the UK learn from ICER in the US?

https://pharmaphorum.com/views-and-analysis/budget-impact-cost-effectiveness-can-uk-learn-icer-us/

The budget impact of new medicines

January 10, 2017

What could be the impact of proposed new ‘budget impact threshold’ for drugs?

The budget impact of new medicines

https://pharmaphorum.com/views-and-analysis/budget-impact-new-medicines/

Fast-track appraisals and Managed Access Agreements

December 23, 2016

Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.

Fast-track appraisals and Managed Access Agreements

https://pharmaphorum.com/views-and-analysis/fast-track-appraisals-managed-access-agreements/

High-value, high-cost drugs: how to pay for them

December 22, 2016

Experts call for urgent development of new drug funding mechanisms.

High-value, high-cost drugs: how to pay for them

https://pharmaphorum.com/views-and-analysis/high-value-high-cost-drugs-pay/

PPRS and devolution: over £60m to Greater Manchester?

August 10, 2016

Does the local NHS in England get its fair share of PPRS money?

PPRS and devolution: over £60m to Greater Manchester?

https://pharmaphorum.com/views-and-analysis/pprs-devolution-60m-greater-manchester/

Access to cancer drugs: planning for every outcome

July 27, 2016

New UK oncology drug assessment procedures examined.

Access to cancer drugs: planning for every outcome

https://pharmaphorum.com/views-and-analysis/access-cancer-drugs-planning-every-outcome/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

NHSE

Creating headroom: can cutting spend on low-value prescriptions fund new drugs?

Budget impact and cost effectiveness: alternatives to NICE and NHSE proposals

Budget impact and cost effectiveness: Can the UK learn from ICER in the US?

The budget impact of new medicines

Fast-track appraisals and Managed Access Agreements

High-value, high-cost drugs: how to pay for them

PPRS and devolution: over £60m to Greater Manchester?

Access to cancer drugs: planning for every outcome

CDD for Biologics Summit 2017

Neoantigen Summit 2017

ICI Summit Europe 2017

6th International GMP, GCP & Quality Control Summit

Inhalation and Respiratory Drug Products Summit

3rd Annual Pre-Filled Syringes Summit

Search

Advanced Search

Trending

NHSE